CC
RARE icon

Centiva Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Centiva Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,554
Closed -$530K – 1548
2021
Q2 		$530K Buy
+5,554
New +$579K 0.01% 808

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Centiva Capital's RARE Position: Q3 2021 in Review

Centiva Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2021, closing a stake of 5,554 shares — an estimated $530K sold.

Centiva Capital first reported a position in RARE in Q2 2021 and held it in 1 quarter. The position peaked at $530K in Q2 2021. 222 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

  • Centiva Capital reported no remaining Ultragenyx Pharmaceutical position as of Q3 2021 after selling out during the quarter.
  • Centiva Capital sold 5,554 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $530K.
  • Centiva Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 1 quarter.
  • Centiva Capital's Ultragenyx Pharmaceutical position peaked at $530K in Q2 2021.
  • 222 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.